Trimipramine

Trimipramine
ATC Code N06AA06
Formula C20H26N2
Molar Mass (g·mol−1) 294,43
Physical State solid
Melting Point (°C) 45
CAS Number 739-71-9
PUB Number 5584
Drugbank ID DB00726
Solubility soluble in water

Basics

Trimipramine is a tricyclic antidepressant (TCA) used to treat depression. It has also been used for its sedative, anxiolytic, and mild antipsychotic effects in the treatment of insomnia, anxiety disorders, and psychosis, respectively. Trimipramine is taken by mouth.

Pharmacology

Pharmacodynamics

The mechanism of action of trimipramine differs from that of other tricyclic antidepressants. Trimipramine works by decreasing the reuptake of norepinephrine and serotonin (5-HT). Although this response occurs immediately, mood does not lift for about two weeks. It is therefore thought that changes in receptor sensitivity in the cerebral cortex and hippocampus are the reason for the antidepressant effect. The hippocampus is part of the limbic system, a part of the brain involved in emotions.

Pharmacokinetics

Absorption is rapid and plasma protein binding is around 93-96%. Metabolism occurs in the liver. The plasma half-life is around 11-18 hours.

Drug Interactions

Trimipramine should not be given with sympathomimetics such as epinephrine (adrenaline), ephedrine, isoprenaline, noradrenaline, phenylephrine, and phenylpropanolamine.

Barbiturate können die Metabolisierungsrate erhöhen. Trimipramin sollte bei Patienten, die eine Therapie für Hyperthyreose erhalten, mit Vorsicht verabreicht werden.

Toxicity

Side effects

Common adverse effects include:

  • Sedation
  • Dry mouth
  • blurred vision
  • Mydriasis
  • decreased lacrimation
  • Constipation
  • hesitation or retention of urine
  • reduced GI motility
  • tachycardia (high heart rate)
  • anticholinergic delirium (especially in the elderly and in Parkinson's disease)
  • Weight gain
  • Orthostatic hypotension
  • Sexual dysfunction including impotence, loss of libido, and other sexual impairments
  • Tremors
  • Dizziness
  • Sweating
  • Anxiety
  • Insomnia
  • restlessness
  • Rash

Toxicological data

LD50 (mouse, oral): 250 mg-kg-1

Sources

  • Drugbank
  • PubChem
  • Aktories, Förstermann, Hofmann, Starke: Allgemeine und spezielle Pharmakologie und Toxikologie, Elsvier, 2017
Markus Falkenstätter

Markus Falkenstätter
Author

Markus Falkenstätter ist Autor zu pharmazeutischen Themen in der Medizin-Redaktion von Medikamio. Er befindet sich im letzten Semester seines Pharmaziestudiums an der Universität Wien und liebt das wissenschaftliche Arbeiten im Bereich der Naturwissenschaften.

Mag. pharm Stefanie Lehenauer

Mag. pharm Stefanie Lehenauer
Lector

Stefanie Lehenauer ist seit 2020 freie Autorin bei Medikamio und studierte Pharmazie an der Universität Wien. Sie arbeitet als Apothekerin in Wien und ihre Leidenschaft sind pflanzliche Arzneimittel und deren Wirkung.

Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über Medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.
Drugs

Search our database for drugs, sorted from A-Z with their effects and ingredients.

Substances

All substances with their common uses, chemical components and medical products which contain them.

Diseases

Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.